Format

Send to

Choose Destination
Rev Endocr Metab Disord. 2017 Mar;18(1):29-40. doi: 10.1007/s11154-016-9402-z.

Dyslipidemia in patients with chronic kidney disease.

Author information

1
Department of Internal Medicine University of Kentucky, Lexington, KY, USA.
2
Division of Endocrinology and Molecular Medicine, University of Kentucky, Lexington, KY, USA.
3
Division of Endocrinology and Molecular Medicine, University of Kentucky, Lexington, KY, USA. Lisa.Tannock@uky.edu.
4
Department of Veterans Affairs, Lexington, KY, USA. Lisa.Tannock@uky.edu.
5
University of Kentucky, 900 S. Limestone, Room 553 CTW, Lexington, KY, 40536-0200, USA. Lisa.Tannock@uky.edu.

Abstract

Chronic kidney disease (CKD) is associated with high risk for cardiovascular disease (CVD). This association is multifactorial, but CKD is often associated with dyslipidemia, which likely contributes. Patients with CKD have dyslipidemia even at early stages of renal dysfunction and dyslipidemia tends to progress with deterioration of kidney function. The dyslipidemia in CKD is largely due to increased triglyceride levels, decreased HDL-C and varying levels of LDL-C. Current management of CKD may also affect lipid levels. Robust clinical trials demonstrate that statins are safe and efficacious in both lipid lowering and prevention of CVD events in pre-end stage CKD and post-transplant. However, there is no evidence of improved CVD outcomes with statin use in dialysis patients. This review will focus on mechanisms underlying dyslipidemia in CKD and clinical trial evidence for lipid lowering therapy in patients with CKD.

KEYWORDS:

Cardiovascular disease; Cholesterol; Chronic kidney disease; Lipids; Renal; Statins

PMID:
28000009
DOI:
10.1007/s11154-016-9402-z
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center